Please Wait.....
Report
Prenatal and Newborn Genetic Testing Market By Product Type (Consumables, Instruments), By Screening (Non-invasive Prenatal Testing, Chronic Villus Sampling, Amniocentesis, Maternal Serum Screening, Others), By Disease (Downs Syndrome, Phenylketonuria, Cystic Fibrosis, Sickle Cell Anemia, others), By End User (Hospital, Maternity and Specialty Clinics, Diagnostic centers): Global Opportunity Analysis and Industry Forecast, 2021-2031
Market Report I 2023-01-01 I 256 Pages I Allied Market Research
The Prenatal and Newborn Genetic Testing Market was valued for $4,891.51 million in 2021 and is estimated to reach $14,727.30 million by 2031, exhibiting a CAGR of 11.5% from 2022 to 2031.Prenatal tests are the medical tests performed during pregnancy which consist of prenatal diagnosis and prenatal screening for detecting problems with pregnancy. It is offered during first or second trimester to women during pregnancy to determine whether the fetus has the possibility to be born with genetic diseases. Newborn testing is considered a public health service done in every U.S. state to diagnose genetic abnormalities in newly born babies. The early detection of genetic diseases may prevent more serious forms of genetic abnormalities and prevent parents from having a disabled child is the primary advantage of prenatal genetic testing. Some of the genetic testing methods include polymerase chain reaction (PCR), fluorescence in-situ hybridization, and array-comparative genomic hybridization.
The prenatal and newborn genetic testing market growth is driven by a rise in the incidence and prevalence of genetic diseases such as cystic fibrosis, Down's syndrome, phenylketonuria, and others and rise in technological advancement in methods of prenatal and newborn genetic testing. The rise in the prevalence of genetic diseases propels high adoption of prenatal and newborn genetic testing for diagnosis of diseases. The National Library of Medicine estimated that phenylketonuria occurs in 1 in 10,000 newborns. For instance, according to the data published by the Centers for Disease Control and Prevention (CDC), in May 2022, sickle cell disease occurs in 1 out of 365 African and American births.
Furthermore, the rise in technological advancement is the key factor that boosts the market growth. For instance, in August 2022, F. Hoffmann-La Roche AG launched the Digital LightCycler System a next-generation digital PCR system that helps physicians to better understand the nature of genetic diseases. This system is designed for performing highly sensitive and precise RNA and DNA analysis.
However, the high cost of non-invasive prenatal testing (NIPT) and other diagnostic tests limits the adoption of prenatal and newborn genetic testing, which, in turn, restrains the market growth. For instance, chronic villus sampling costs around $3,050, and amniocentesis costs about $4,100 without insurance.
Increased medical demands in developed countries such as U.S., Canada, and Germany and growth opportunities in emerging markets, on the other hand, are expected to create immense opportunities for the prenatal and newborn genetic testing market during the forecast period. Moreover, a rise in awareness regarding the use of prenatal and newborn genetic testing for the diagnosis and monitoring of seizures is expected to propel the market growth during the forecast period.
The prenatal and newborn genetic testing market is segmented into product type, screening, disease, and end user. On the basis of product type, the market is bifurcated into instruments and consumables. On the basis of screening, the market is segmented into non-invasive prenatal testing (NIPT), chronic villus sampling (CVS), amniocentesis, maternal serum screening (MSS), and others. On the basis of disease, the market is categorized into Down's syndrome, phenylketonuria, cystic fibrosis, sickle cell anemia, and others. On the basis of end users, the market is fragmented into hospitals, maternity and specialty clinics, and diagnostic centers.
On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).
Major key players that operate in the global Prenatal and newborn genetic testing Market are Bio-Rad Laboratories, Inc., PerkinElmer Inc., Natera, Inc., Quest Diagnostics Incorporated, F. Hoffmann-La Roche AG, Mettler Toledo, Laboratory Corporation of America Holdings, Thermo Fisher Scientific Inc., Abbott Laboratories, and BGI Group.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the prenatal and newborn genetic testing market analysis from 2021 to 2031 to identify the prevailing prenatal and newborn genetic testing market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the prenatal and newborn genetic testing market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global prenatal and newborn genetic testing market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product Type
- Consumables
- Instruments
By Screening
- Non-invasive Prenatal Testing
- Chronic Villus Sampling
- Amniocentesis
- Maternal Serum Screening
- Others
By Disease
- others
- Downs Syndrome
- Phenylketonuria
- Cystic Fibrosis
- Sickle Cell Anemia
By End User
- Hospital
- Maternity and Specialty Clinics
- Diagnostic centers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Bio-Rad Laboratories, Inc.
- Mettler Toledo
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Laboratory Corporation of America Holdings
- BGI Group
- PerkinElmer Inc.
- Natera, Inc.
- F. Hoffmann-La Roche AG
- Quest Diagnostics Incorporated
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate bargaining power of buyers
3.3.3. Moderate threat of substitutes
3.3.4. High threat of new entrants
3.3.5. Moderate intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of genetic diseases among infants
3.4.1.2. Rise in demand for non-invasive prenatal testing
3.4.2. Restraints
3.4.2.1. High cost of complex prenatal and newborn genetic testing
3.4.3. Opportunities
3.4.3.1. Lucrative growth opportunities in developing countries
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Consumables
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Instruments
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING
5.1. Overview
5.1.1. Market size and forecast
5.2. Non-invasive Prenatal Testing
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Chronic Villus Sampling
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Amniocentesis
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Maternal Serum Screening
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Others
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
CHAPTER 6: PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE
6.1. Overview
6.1.1. Market size and forecast
6.2. Downs Syndrome
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Phenylketonuria
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Cystic Fibrosis
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Sickle Cell Anemia
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
6.6. others
6.6.1. Key market trends, growth factors and opportunities
6.6.2. Market size and forecast, by region
6.6.3. Market share analysis by country
CHAPTER 7: PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospital
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Maternity and Specialty Clinics
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Diagnostic centers
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key trends and opportunities
8.2.2. Market size and forecast, by Product Type
8.2.3. Market size and forecast, by Screening
8.2.4. Market size and forecast, by Disease
8.2.5. Market size and forecast, by End User
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Key market trends, growth factors and opportunities
8.2.6.1.2. Market size and forecast, by Product Type
8.2.6.1.3. Market size and forecast, by Screening
8.2.6.1.4. Market size and forecast, by Disease
8.2.6.1.5. Market size and forecast, by End User
8.2.6.2. Canada
8.2.6.2.1. Key market trends, growth factors and opportunities
8.2.6.2.2. Market size and forecast, by Product Type
8.2.6.2.3. Market size and forecast, by Screening
8.2.6.2.4. Market size and forecast, by Disease
8.2.6.2.5. Market size and forecast, by End User
8.2.6.3. Mexico
8.2.6.3.1. Key market trends, growth factors and opportunities
8.2.6.3.2. Market size and forecast, by Product Type
8.2.6.3.3. Market size and forecast, by Screening
8.2.6.3.4. Market size and forecast, by Disease
8.2.6.3.5. Market size and forecast, by End User
8.3. Europe
8.3.1. Key trends and opportunities
8.3.2. Market size and forecast, by Product Type
8.3.3. Market size and forecast, by Screening
8.3.4. Market size and forecast, by Disease
8.3.5. Market size and forecast, by End User
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Key market trends, growth factors and opportunities
8.3.6.1.2. Market size and forecast, by Product Type
8.3.6.1.3. Market size and forecast, by Screening
8.3.6.1.4. Market size and forecast, by Disease
8.3.6.1.5. Market size and forecast, by End User
8.3.6.2. France
8.3.6.2.1. Key market trends, growth factors and opportunities
8.3.6.2.2. Market size and forecast, by Product Type
8.3.6.2.3. Market size and forecast, by Screening
8.3.6.2.4. Market size and forecast, by Disease
8.3.6.2.5. Market size and forecast, by End User
8.3.6.3. UK
8.3.6.3.1. Key market trends, growth factors and opportunities
8.3.6.3.2. Market size and forecast, by Product Type
8.3.6.3.3. Market size and forecast, by Screening
8.3.6.3.4. Market size and forecast, by Disease
8.3.6.3.5. Market size and forecast, by End User
8.3.6.4. Italy
8.3.6.4.1. Key market trends, growth factors and opportunities
8.3.6.4.2. Market size and forecast, by Product Type
8.3.6.4.3. Market size and forecast, by Screening
8.3.6.4.4. Market size and forecast, by Disease
8.3.6.4.5. Market size and forecast, by End User
8.3.6.5. Spain
8.3.6.5.1. Key market trends, growth factors and opportunities
8.3.6.5.2. Market size and forecast, by Product Type
8.3.6.5.3. Market size and forecast, by Screening
8.3.6.5.4. Market size and forecast, by Disease
8.3.6.5.5. Market size and forecast, by End User
8.3.6.6. Rest of Europe
8.3.6.6.1. Key market trends, growth factors and opportunities
8.3.6.6.2. Market size and forecast, by Product Type
8.3.6.6.3. Market size and forecast, by Screening
8.3.6.6.4. Market size and forecast, by Disease
8.3.6.6.5. Market size and forecast, by End User
8.4. Asia-Pacific
8.4.1. Key trends and opportunities
8.4.2. Market size and forecast, by Product Type
8.4.3. Market size and forecast, by Screening
8.4.4. Market size and forecast, by Disease
8.4.5. Market size and forecast, by End User
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Key market trends, growth factors and opportunities
8.4.6.1.2. Market size and forecast, by Product Type
8.4.6.1.3. Market size and forecast, by Screening
8.4.6.1.4. Market size and forecast, by Disease
8.4.6.1.5. Market size and forecast, by End User
8.4.6.2. China
8.4.6.2.1. Key market trends, growth factors and opportunities
8.4.6.2.2. Market size and forecast, by Product Type
8.4.6.2.3. Market size and forecast, by Screening
8.4.6.2.4. Market size and forecast, by Disease
8.4.6.2.5. Market size and forecast, by End User
8.4.6.3. Australia
8.4.6.3.1. Key market trends, growth factors and opportunities
8.4.6.3.2. Market size and forecast, by Product Type
8.4.6.3.3. Market size and forecast, by Screening
8.4.6.3.4. Market size and forecast, by Disease
8.4.6.3.5. Market size and forecast, by End User
8.4.6.4. India
8.4.6.4.1. Key market trends, growth factors and opportunities
8.4.6.4.2. Market size and forecast, by Product Type
8.4.6.4.3. Market size and forecast, by Screening
8.4.6.4.4. Market size and forecast, by Disease
8.4.6.4.5. Market size and forecast, by End User
8.4.6.5. South Korea
8.4.6.5.1. Key market trends, growth factors and opportunities
8.4.6.5.2. Market size and forecast, by Product Type
8.4.6.5.3. Market size and forecast, by Screening
8.4.6.5.4. Market size and forecast, by Disease
8.4.6.5.5. Market size and forecast, by End User
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Key market trends, growth factors and opportunities
8.4.6.6.2. Market size and forecast, by Product Type
8.4.6.6.3. Market size and forecast, by Screening
8.4.6.6.4. Market size and forecast, by Disease
8.4.6.6.5. Market size and forecast, by End User
8.5. LAMEA
8.5.1. Key trends and opportunities
8.5.2. Market size and forecast, by Product Type
8.5.3. Market size and forecast, by Screening
8.5.4. Market size and forecast, by Disease
8.5.5. Market size and forecast, by End User
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Key market trends, growth factors and opportunities
8.5.6.1.2. Market size and forecast, by Product Type
8.5.6.1.3. Market size and forecast, by Screening
8.5.6.1.4. Market size and forecast, by Disease
8.5.6.1.5. Market size and forecast, by End User
8.5.6.2. Saudi Arabia
8.5.6.2.1. Key market trends, growth factors and opportunities
8.5.6.2.2. Market size and forecast, by Product Type
8.5.6.2.3. Market size and forecast, by Screening
8.5.6.2.4. Market size and forecast, by Disease
8.5.6.2.5. Market size and forecast, by End User
8.5.6.3. South Africa
8.5.6.3.1. Key market trends, growth factors and opportunities
8.5.6.3.2. Market size and forecast, by Product Type
8.5.6.3.3. Market size and forecast, by Screening
8.5.6.3.4. Market size and forecast, by Disease
8.5.6.3.5. Market size and forecast, by End User
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Key market trends, growth factors and opportunities
8.5.6.4.2. Market size and forecast, by Product Type
8.5.6.4.3. Market size and forecast, by Screening
8.5.6.4.4. Market size and forecast, by Disease
8.5.6.4.5. Market size and forecast, by End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2021
CHAPTER 10: COMPANY PROFILES
10.1. Bio-Rad Laboratories, Inc.
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.2. PerkinElmer Inc.
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. Natera, Inc.
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.4. Quest Diagnostics Incorporated
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. F. Hoffmann-La Roche AG
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.5.7. Key strategic moves and developments
10.6. Mettler Toledo
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. Laboratory Corporation of America Holdings
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.8. Thermo Fisher Scientific Inc.
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.9. Abbott Laboratories
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.10. BGI Group
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
LIST OF TABLES
TABLE 01. GLOBAL PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 02. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR CONSUMABLES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 03. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR INSTRUMENTS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 04. GLOBAL PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 05. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR NON-INVASIVE PRENATAL TESTING, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 06. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR CHRONIC VILLUS SAMPLING, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 07. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR AMNIOCENTESIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 08. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR MATERNAL SERUM SCREENING, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 09. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 10. GLOBAL PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 11. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR DOWNS SYNDROME, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR PHENYLKETONURIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 13. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR CYSTIC FIBROSIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR SICKLE CELL ANEMIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 15. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 16. GLOBAL PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 17. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR HOSPITAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 18. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR MATERNITY AND SPECIALTY CLINICS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 19. PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 20. PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 21. NORTH AMERICA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 22. NORTH AMERICA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 23. NORTH AMERICA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 24. NORTH AMERICA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 25. NORTH AMERICA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 26. U.S. PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 27. U.S. PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 28. U.S. PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 29. U.S. PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 30. CANADA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 31. CANADA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 32. CANADA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 33. CANADA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 34. MEXICO PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 35. MEXICO PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 36. MEXICO PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 37. MEXICO PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 38. EUROPE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 39. EUROPE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 40. EUROPE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 41. EUROPE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 42. EUROPE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 43. GERMANY PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 44. GERMANY PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 45. GERMANY PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 46. GERMANY PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 47. FRANCE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 48. FRANCE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 49. FRANCE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 50. FRANCE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 51. UK PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 52. UK PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 53. UK PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 54. UK PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 55. ITALY PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 56. ITALY PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 57. ITALY PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 58. ITALY PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 59. SPAIN PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 60. SPAIN PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 61. SPAIN PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 62. SPAIN PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 63. REST OF EUROPE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 64. REST OF EUROPE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 65. REST OF EUROPE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 66. REST OF EUROPE PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 67. ASIA-PACIFIC PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 68. ASIA-PACIFIC PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 69. ASIA-PACIFIC PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 70. ASIA-PACIFIC PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 71. ASIA-PACIFIC PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 72. JAPAN PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 73. JAPAN PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 74. JAPAN PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 75. JAPAN PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 76. CHINA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 77. CHINA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 78. CHINA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 79. CHINA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 80. AUSTRALIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 81. AUSTRALIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 82. AUSTRALIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 83. AUSTRALIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 84. INDIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 85. INDIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 86. INDIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 87. INDIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 88. SOUTH KOREA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 89. SOUTH KOREA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 90. SOUTH KOREA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 91. SOUTH KOREA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 92. REST OF ASIA-PACIFIC PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 93. REST OF ASIA-PACIFIC PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 94. REST OF ASIA-PACIFIC PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 95. REST OF ASIA-PACIFIC PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 96. LAMEA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 97. LAMEA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 98. LAMEA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 99. LAMEA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 100. LAMEA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 101. BRAZIL PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 102. BRAZIL PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 103. BRAZIL PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 104. BRAZIL PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 105. SAUDI ARABIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 106. SAUDI ARABIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 107. SAUDI ARABIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 108. SAUDI ARABIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 109. SOUTH AFRICA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 110. SOUTH AFRICA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 111. SOUTH AFRICA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 112. SOUTH AFRICA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 113. REST OF LAMEA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 114. REST OF LAMEA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021-2031 (REVENUE, $MILLION)
TABLE 115. REST OF LAMEA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021-2031 (REVENUE, $MILLION)
TABLE 116. REST OF LAMEA PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
TABLE 117. BIO-RAD LABORATORIES, INC.: KEY EXECUTIVES
TABLE 118. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 119. BIO-RAD LABORATORIES, INC.: PRODUCT SEGMENTS
TABLE 120. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 121. PERKINELMER INC.: KEY EXECUTIVES
TABLE 122. PERKINELMER INC.: COMPANY SNAPSHOT
TABLE 123. PERKINELMER INC.: PRODUCT SEGMENTS
TABLE 124. PERKINELMER INC.: PRODUCT PORTFOLIO
TABLE 125. PERKINELMER INC.: KEY STRATERGIES
TABLE 126. NATERA, INC.: KEY EXECUTIVES
TABLE 127. NATERA, INC.: COMPANY SNAPSHOT
TABLE 128. NATERA, INC.: PRODUCT SEGMENTS
TABLE 129. NATERA, INC.: PRODUCT PORTFOLIO
TABLE 130. QUEST DIAGNOSTICS INCORPORATED: KEY EXECUTIVES
TABLE 131. QUEST DIAGNOSTICS INCORPORATED: COMPANY SNAPSHOT
TABLE 132. QUEST DIAGNOSTICS INCORPORATED: PRODUCT SEGMENTS
TABLE 133. QUEST DIAGNOSTICS INCORPORATED: PRODUCT PORTFOLIO
TABLE 134. F. HOFFMANN-LA ROCHE AG: KEY EXECUTIVES
TABLE 135. F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
TABLE 136. F. HOFFMANN-LA ROCHE AG: PRODUCT SEGMENTS
TABLE 137. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
TABLE 138. F. HOFFMANN-LA ROCHE AG: KEY STRATERGIES
TABLE 139. METTLER TOLEDO: KEY EXECUTIVES
TABLE 140. METTLER TOLEDO: COMPANY SNAPSHOT
TABLE 141. METTLER TOLEDO: PRODUCT SEGMENTS
TABLE 142. METTLER TOLEDO: PRODUCT PORTFOLIO
TABLE 143. LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY EXECUTIVES
TABLE 144. LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
TABLE 145. LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT SEGMENTS
TABLE 146. LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
TABLE 147. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
TABLE 148. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 149. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
TABLE 150. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 151. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 152. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 153. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 154. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 155. BGI GROUP: KEY EXECUTIVES
TABLE 156. BGI GROUP: COMPANY SNAPSHOT
TABLE 157. BGI GROUP: PRODUCT SEGMENTS
TABLE 158. BGI GROUP: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031
FIGURE 02. SEGMENTATION OF PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031
FIGURE 03. TOP INVESTMENT POCKETS IN PRENATAL AND NEWBORN GENETIC TESTING MARKET (2022-2031)
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
FIGURE 06. MODERATE THREAT OF SUBSTITUTES
FIGURE 07. HIGH THREAT OF NEW ENTRANTS
FIGURE 08. MODERATE INTENSITY OF RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALPRENATAL AND NEWBORN GENETIC TESTING MARKET
FIGURE 10. PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY PRODUCT TYPE, 2021(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR CONSUMABLES, BY COUNTRY 2021-2031(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR INSTRUMENTS, BY COUNTRY 2021-2031(%)
FIGURE 13. PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY SCREENING, 2021(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR NON-INVASIVE PRENATAL TESTING, BY COUNTRY 2021-2031(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR CHRONIC VILLUS SAMPLING, BY COUNTRY 2021-2031(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR AMNIOCENTESIS, BY COUNTRY 2021-2031(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR MATERNAL SERUM SCREENING, BY COUNTRY 2021-2031(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
FIGURE 19. PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY DISEASE, 2021(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR DOWNS SYNDROME, BY COUNTRY 2021-2031(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR PHENYLKETONURIA, BY COUNTRY 2021-2031(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR CYSTIC FIBROSIS, BY COUNTRY 2021-2031(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR SICKLE CELL ANEMIA, BY COUNTRY 2021-2031(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
FIGURE 25. PRENATAL AND NEWBORN GENETIC TESTING MARKET, BY END USER, 2021(%)
FIGURE 26. COMPARATIVE SHARE ANALYSIS OF PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR HOSPITAL, BY COUNTRY 2021-2031(%)
FIGURE 27. COMPARATIVE SHARE ANALYSIS OF PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR MATERNITY AND SPECIALTY CLINICS, BY COUNTRY 2021-2031(%)
FIGURE 28. COMPARATIVE SHARE ANALYSIS OF PRENATAL AND NEWBORN GENETIC TESTING MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY 2021-2031(%)
FIGURE 29. PRENATAL AND NEWBORN GENETIC TESTING MARKET BY REGION, 2021
FIGURE 30. U.S. PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 31. CANADA PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 32. MEXICO PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 33. GERMANY PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 34. FRANCE PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 35. UK PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 36. ITALY PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 37. SPAIN PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 38. REST OF EUROPE PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 39. JAPAN PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 40. CHINA PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 41. AUSTRALIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 42. INDIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 43. SOUTH KOREA PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 44. REST OF ASIA-PACIFIC PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 45. BRAZIL PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 46. SAUDI ARABIA PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 47. SOUTH AFRICA PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 48. REST OF LAMEA PRENATAL AND NEWBORN GENETIC TESTING MARKET, 2021-2031 ($MILLION)
FIGURE 49. TOP WINNING STRATEGIES, BY YEAR
FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 52. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 53. COMPETITIVE DASHBOARD
FIGURE 54. COMPETITIVE HEATMAP: PRENATAL AND NEWBORN GENETIC TESTING MARKET
FIGURE 55. TOP PLAYER POSITIONING, 2021
FIGURE 56. BIO-RAD LABORATORIES, INC.: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 57. BIO-RAD LABORATORIES, INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 58. BIO-RAD LABORATORIES, INC.: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 59. PERKINELMER INC.: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 60. PERKINELMER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 61. PERKINELMER INC.: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 62. NATERA, INC.: NET SALES, 2019-2021 ($MILLION)
FIGURE 63. NATERA, INC.: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 64. QUEST DIAGNOSTICS INCORPORATED: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 65. F. HOFFMANN-LA ROCHE AG: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 66. F. HOFFMANN-LA ROCHE AG: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 67. METTLER TOLEDO: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 68. METTLER TOLEDO: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 69. LABORATORY CORPORATION OF AMERICA HOLDINGS: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 70. LABORATORY CORPORATION OF AMERICA HOLDINGS: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 71. LABORATORY CORPORATION OF AMERICA HOLDINGS: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 72. THERMO FISHER SCIENTIFIC INC.: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 73. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 74. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 75. ABBOTT LABORATORIES: NET SALES, 2019-2021 ($MILLION)
FIGURE 76. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 77. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2021 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security